-
Je něco špatně v tomto záznamu ?
Malignancy Rates in Thyroid Nodules Classified as Bethesda III and IV; Correlating Fine Needle Aspiration Cytology with Histopathology
C. Pereira
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Medline Complete (EBSCOhost)
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- MeSH
- lidé MeSH
- tenkojehlová biopsie MeSH
- uzly štítné žlázy * diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Fine needle aspiration cytology (FNAC) is an integral part in the diagnostic work up of thyroid nodules. FNAC reports are based on Bethesda system for thyroid cytopathology which is one of the most commonly used systems worldwide. The main objective of the present study was to evaluate the malignancy rates in Bethesda category III and IV thyroid nodules over a six-year period. 642 thyroid FNAC were performed over a six-year period. The medical records of all these patients were reviewed using electronic patient records. Cases reported to have Bethesda category III and IV were included in the study. Data for these patients were reviewed to determine the relationship between these categories and thyroid cancer. There were 41 cases of category III of which 19 underwent surgery and the malignancy rates were found to be 26.3%. Category IV consisted of 50 cases of which 45 underwent surgery and the malignancy rates were 26.6%. The results from our study are similar to findings in larger multicentric studies which found that malignancy rates for Bethesda category III and IV were 10-30% and 25-40%, respectively.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22027753
- 003
- CZ-PrNML
- 005
- 20221207151442.0
- 007
- ta
- 008
- 221206s2022 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/23362936.2022.22 $2 doi
- 035 __
- $a (PubMed)36416462
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Pereira, Chirag $u Department of General Surgery, Royal Lancaster Infirmary, Lancaster, United Kingdom. chirag.pereira@mbht.nhs.uk
- 245 10
- $a Malignancy Rates in Thyroid Nodules Classified as Bethesda III and IV; Correlating Fine Needle Aspiration Cytology with Histopathology / $c C. Pereira
- 520 9_
- $a Fine needle aspiration cytology (FNAC) is an integral part in the diagnostic work up of thyroid nodules. FNAC reports are based on Bethesda system for thyroid cytopathology which is one of the most commonly used systems worldwide. The main objective of the present study was to evaluate the malignancy rates in Bethesda category III and IV thyroid nodules over a six-year period. 642 thyroid FNAC were performed over a six-year period. The medical records of all these patients were reviewed using electronic patient records. Cases reported to have Bethesda category III and IV were included in the study. Data for these patients were reviewed to determine the relationship between these categories and thyroid cancer. There were 41 cases of category III of which 19 underwent surgery and the malignancy rates were found to be 26.3%. Category IV consisted of 50 cases of which 45 underwent surgery and the malignancy rates were 26.6%. The results from our study are similar to findings in larger multicentric studies which found that malignancy rates for Bethesda category III and IV were 10-30% and 25-40%, respectively.
- 650 _7
- $a lidé $7 D006801
- 650 _7
- $a tenkojehlová biopsie $7 D044963
- 650 17
- $a uzly štítné žlázy $x diagnóza $7 D016606
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00013414 $t Prague medical report $x 1214-6994 $g Roč. 123, č. 4 (2022), s. 243-249
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36416462 $y Pubmed
- 910 __
- $a ABA008 $b A 7 $c 1071 $y p $z 0
- 990 __
- $a 20221206 $b ABA008
- 991 __
- $a 20221207151437 $b ABA008
- 999 __
- $a ok $b bmc $g 1867739 $s 1179066
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 123 $c 4 $d 243-249 $e - $i 1214-6994 $m Prague Medical Report $n Prague Med. Rep. $x MED00013414
- LZP __
- $b NLK138 $a Pubmed-20221206